No black box warning on record for Nicardipine Hydrochloride

As of the latest FDA labeling reviewed, Nicardipine Hydrochloride (NICARDIPINE HYDROCHLORIDE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Nicardipine Hydrochloride medicine page for the complete safety profile.

Other warnings & precautions

WARNINGS Increased Angina About 7% of patients in short-term, placebo-controlled angina trials have developed increased frequency, duration or severity of angina on starting nicardipine hydrochloride capsules or at the time of dosage increases, compared with 4% of patients on placebo. Comparisons with beta-blockers also show a greater frequency of increased angina, 4% vs 1%. The mechanism of this

No black box warning on record for Nicardipine Hydrochloride

Other warnings & precautions

WARNINGS Increased Angina About 7% of patients in short-term, placebo-controlled angina trials have developed increased frequency, duration or severity of angina on starting nicardipine hydrochloride capsules or at the time of dosage increases, compared with 4% of patients on placebo. Comparisons with beta-blockers also show a greater frequency of increased angina, 4% vs 1%. The mechanism of this

Nicardipine Hydrochloride Black Box Warning

No black box warning on record for Nicardipine Hydrochloride

Other warnings & precautions

Nicardipine Hydrochloride Black Box Warning

No black box warning on record for Nicardipine Hydrochloride

Other warnings & precautions